Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.

NCT00088140 · ClinicalTrials.gov registry record · Phase 2

A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients

A Phase 2 study of Hepatitis C, Chronic, sponsored by Conatus Pharmaceuticals.

Completed
Registry status
Phase 2
Development phase
204
Enrollment target
15
Study locations

NCT00088140: Completed Phase 2 study of Hepatitis C, Chronic, sponsored by Conatus Pharmaceuticals.

NCT00088140 is a Phase 2 study of Hepatitis C, Chronic that has completed, run by Conatus Pharmaceuticals. The registered enrollment target is 204 participants, below the 368-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (45% lower). The trial reports 15 study locations across 11 states. According to ClinicalTrials.gov, the official US trial registry.

View on ClinicalTrials.gov ↗

View your shortlist →

The verdict

NCT00088140, a Phase 2 study of Hepatitis C, Chronic, has completed, sponsored by Conatus Pharmaceuticals.

COMPLETED
Registry status
Phase 2
Development phase
204 participants
Enrollment target
15
Study locations

Study Summary

The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.

Conditions Studied

Hepatitis C, Chronic

Interventions

  • DRUG Placebo
  • DRUG IDN-6556

Study Locations (15)

California

  • Scripps Clinic - La Jolla
  • California Pacific Medical Center - San Francisco
  • University of California, San Francisco - San Francisco

North Carolina

  • University of North Carolina - Chapel Hill
  • Duke University Medical Center - Durham

Ohio

  • University of Cincinnati - Cincinnati
  • Metrohealth Medical Center - Cleveland

Arizona

  • Mayo Clinic Hospital - Phoenix

Florida

  • University of Miami - Miami

Indiana

  • Indiana University School of Medicine - Indianapolis

Massachusetts

  • Beth Israel Deaconness Medical Center - Boston

Michigan

  • Henry Ford Hospital - Detroit

Trial Details

FieldValue
Enrollment Target 204 participants
Start Date 2004-07
Est. Completion 2005-10
Phase Phase 2
Conatus Pharmaceuticals

16 total trials

What the finished NCT00088140 record still lists

NCT00088140 is an interventional study that assigns participants to a tested intervention. The registered 204 participants enrollment target is mid-sized for trials with a published cap, below the 368-participant average among 26 other Hepatitis C, Chronic trials with a reported enrollment target (45% lower).

The record links to 1 condition, with Hepatitis C, Chronic appearing as the primary indexed condition, and to 2 interventions - of which Placebo is the first listed.

NCT00088140 lists 15 locations in 11 states (California, North Carolina, Ohio).

Frequently Asked Questions

What is clinical trial NCT00088140 about?

NCT00088140 is a clinical study titled "A Caspase Inhibitor in Chronic Hepatitis C (HCV) Patients". The purpose of this study is to determine if IDN-6556, when given orally, is safe and effective in patients with chronic hepatitis C virus infection.

What is the current status of trial NCT00088140?

This trial is currently completed. It is a Phase 2 study. The enrollment target is 204 participants. The study started on 2004-07. Estimated completion is 2005-10.

What conditions does trial NCT00088140 study?

This clinical trial studies the following conditions: Hepatitis C, Chronic.

What interventions are being tested in trial NCT00088140?

The interventions under investigation include: Placebo (DRUG), IDN-6556 (DRUG).

Who is sponsoring clinical trial NCT00088140?

This trial is sponsored by Conatus Pharmaceuticals, which has 16 total clinical trials registered on ClinicalTrials.gov.

Where is trial NCT00088140 being conducted?

This trial has 15 study locations across Arizona, California, Florida, Indiana, Massachusetts. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.

Learn More About Clinical Trials

Similar trials for Hepatitis C, Chronic

Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.

Where NCT00088140's enrollment target sits among peer trials

204 11th of 26 higher than 16 of 26 other Hepatitis C, Chronic trials

participants (enrollment target), bucketed by value

Each bar is a band; taller bars hold more other Hepatitis C, Chronic trials. The dashed line + filled bar mark this entry. Hover or tap any bar for its full count and share, and where it sits relative to this entry.

Source ClinicalTrials.gov registry export · 2026-08-08

Nationwide trials with similar profiles

Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.

Similar enrollment target

  • NCT03481010 · 204 participants · NA

    Periacetabular Osteotomy With and Without Arthroscopic Management of Central Compartment Pathology

  • NCT04249830 · 204 participants · NA

    Stem Cell Transplant From Donors After Alpha Beta Cell Depletion in Children and Young Adults

  • NCT04503395 · 204 participants · NA

    ShOrt neCK AAA RAndomized Trial - ESAR and FEVAR: SOCRATES

  • NCT04793776 · 204 participants · NA

    Manage Emotions to Reduce Aggression (MERA)

Similar registry start date

  • NCT05988463 · started 2027-01-01 · Phase 1

    Dose-Escalation Study of Artesunate Patients With IPF

  • NCT07219706 · started 2026-12-10 · NA

    Dietary Fiber and Time Restricted Eating

  • NCT02831335 · started 2026-12-01

    Technical Development of Multi-Parametric Renocerebral MRI

  • NCT05962346 · started 2026-12 · NA

    Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia

Related registry views

Source: ClinicalTrials.gov NCT00088140, the US trial registry maintained by the National Library of Medicine. NCT00088140 (mid enrollment · multi site footprint · completed) retrieved and formatted by PlainTrial, see methodology.